



Oxis Turbohaler advertisement.

[s.l.]: [s.n.], 2025-12-29

<https://digital.library.wisc.edu/1711.dl/4R5IFDHLOZFTS9B>

<http://rightsstatements.org/vocab/InC/1.0/>

The libraries provide public access to a wide range of material, including online exhibits, digitized collections, archival finding aids, our catalog, online articles, and a growing range of materials in many media.

When possible, we provide rights information in catalog records, finding aids, and other metadata that accompanies collections or items. However, it is always the user's obligation to evaluate copyright and rights issues in light of their own use.



A matter of control

Oxis Turbuhaler® (formoterol dry powder inhaler). Abbreviated Prescribing Information: See local Prescribing Information for full details, as Prescribing Information may vary from country to country.

Medicinal Product: Oxis Turbuhaler® 4,5 µg/dose; Oxis Turbuhaler® 9 µg/dose.

Properties: An inhaled selective β_2 -adrenergic agonist that produces relaxation of bronchial smooth muscle. The bronchodilating effect sets in rapidly, within 1-3 minutes after inhalation, and has a mean duration of 12 hours.

Indication: Treatment and prevention of reversible airways obstruction. Oxis Turbuhaler is intended for use in maintenance therapy in addition to corticosteroids.

Contra-indications: Hypersensitivity to formoterol or to inhaled lactose.

Dosage: Dosage should be individualized. Adults and elderly: Normal dosage: 4,5-9 µg once or twice daily. The dose can be administered in the morning and/or at night. The nightly dosage can be taken to prevent awakening due to nocturnal asthma symptoms. Some patients may need 18 µg once or twice daily. A daily dose above 36 is not recommended. Children: The use in children has not been documented.

Warnings and Precautions: Caution should be observed in patients with thyrotoxicosis, severe cardiovascular disorder, prolongation of the QTc-interval. The hypokalemic effect of Oxis Turbuhaler like other β_2 -agonists may be potentiated by concomitant treatment with xanthine derivatives, corticosteroids, and diuretics. As formoterol is primarily eliminated via metabolism an increased exposure can be expected in patients with severe liver cirrhosis.

Note: The patient should seek medical advice if a previously effective dosage regimen no longer gives the same relief.

Undesirable effects: Common: headache, palpitations and tremor. Tremor and palpitations reduce with regular therapy. Less common: agitation, restlessness, sleep disturbances, muscle cramps and tachycardia. Rare: exanthema, urticaria, pruritus, hypokalemia. Paradoxical bronchospasm in very rare cases as with all inhalation therapy. In isolated cases: Nausea, taste disturbances, dizziness, angina pectoris, variations in the blood pressure and hyperglycemia. Treatment with β_2 -sympathomimetics may result in an increase in blood levels of insulin, free fatty acids, glycerol and ketone bodies.

Interactions: Beta-adrenergic blockers (including eye-drops) can weaken or inhibit the effect of Oxis Turbuhaler. In addition L-Dopa, L-thyroxine, oxytocin and alcohol can impair cardiac tolerance towards β_2 -sympathomimetics. Concomitant treatment with quinidine, disopyramide, procainamide, phenothiazines, antihistamines (terfenadine) monoamine oxidase inhibitors and tricyclic antidepressives can prolong the QTc-interval and increase the risk of ventricular arrhythmias.

Legal category: POM. Further information is available on request from Astra Draco or the local Astra company. Oxis Turbuhaler® is a registered trademark owned by Astra AB. Other trademarks are Oxis Turbohaler®, Oxeze Turbuhaler®, Oxeze Turbohaler® and Oxez Turbuhaler®.




Formoterol

Oxis® *Turbuhaler®*

A new member of the Turbuhaler team.

Formoterol, delivered by the easy-to-use Turbuhaler system, acts fast – within one to three minutes – and sustains bronchodilation for twelve hours.



Oxis Turbuhaler®
Long-lasting symptom relief – fast and easy

ASTRA

Astra Draco AB, P.O. Box 34, S-221 00 Lund, Sweden.